BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 29582423)

  • 1. A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas.
    Wirthschaft P; Bode J; Simon AEM; Hoffmann E; van Laack R; Krüwel T; Dietrich F; Bucher D; Hahn A; Sahm F; Breckwoldt MO; Kurz FT; Hielscher T; Fischer B; Dross N; Ruiz de Almodovar C; von Deimling A; Herold-Mende C; Plass C; Boulant S; Wiestler B; Reifenberger G; Lichter P; Wick W; Tews B
    Int J Cancer; 2018 Sep; 143(5):1176-1187. PubMed ID: 29582423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
    Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
    World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas.
    Huang GH; Du L; Li N; Zhang Y; Xiang Y; Tang JH; Xia S; Zhang EE; Lv SQ
    Cancer Lett; 2018 Sep; 432():93-102. PubMed ID: 29885519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro.
    Dittmann LM; Danner A; Gronych J; Wolter M; Stühler K; Grzendowski M; Becker N; Bageritz J; Goidts V; Toedt G; Felsberg J; Sabel MC; Barbus S; Reifenberger G; Lichter P; Tews B
    Oncogene; 2012 Jul; 31(29):3409-18. PubMed ID: 22158042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
    Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
    J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
    Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
    Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
    Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
    Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastomas harboring gene fusions detected by next-generation sequencing.
    Woo HY; Na K; Yoo J; Chang JH; Park YN; Shim HS; Kim SH
    Brain Tumor Pathol; 2020 Oct; 37(4):136-144. PubMed ID: 32761533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
    Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtyping of tumors from patients with familial glioma.
    Ruiz VY; Praska CE; Armstrong G; Kollmeyer TM; Yamada S; Decker PA; Kosel ML; Eckel-Passow JE; Lachance DH; Bainbridge MN; Melin BS; Bondy ML; Jenkins RB;
    Neuro Oncol; 2018 May; 20(6):810-817. PubMed ID: 29040662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma.
    Szeliga M
    Neurochem Int; 2022 Feb; 153():105256. PubMed ID: 34968631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma.
    Chang YZ; Chai RC; Pang B; Chang X; An SY; Zhang KN; Jiang T; Wang YZ
    Cancer Lett; 2021 Jul; 511():36-46. PubMed ID: 33933553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.